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Prospects for Harmonizing Regulatory Science (RS) Programs in Europe, Japan, 
and the United States to Advance Regenerative Medicine (RM) 
 
Christopher-Paul Milne, James Mittra, Naoko Kojima, Daisuke Sugiyama, Josephine Awatin, and 
Gabrielle Simmons 
 
INTRODUCTION 
Though great progress has been made in medicine, current evidence-based and palliative 
treatments are unable to keep pace with patients' needs, especially given aging populations. 
There are few effective ways to treat the root causes of many diseases, injuries and congenital 
conditions. In many cases, clinicians can only manage patients' symptoms using conventional 
therapy. Regenerative medicine (RM) is a game-changing area of medicine with the potential to 
repair damaged tissues and organs, and bring hope to patients with debilitating illness. The 
body’s ability to rebuild itself at many different levels using complex mechanisms means RM 
promises to be a valuable tool in most medical specialties1   
RM itself is not new, and its underlying technologies are based on over 50 years of 
research in stem cell biology, molecular biology, engineering, advanced materials, immunology 
and genomics. Its growing importance was recently highlighted by a government report to the 
US Congress showing that 22 of 27 institutes within the National Institutes of Health (NIH) 
funded RM research projects from 2012 through 2014, and that for six of these institutes RM 
awards comprised 7% or more of research funding, including a quarter of the total funding 
awards from the National Heart, Lung, and Blood Institute.2  The field has taken a major leap 
with the clinical introduction of cell and gene-based therapies, which can cure underlying 
disease, rather than simply manage symptoms or slow disease progression.3  With its power to 
restore and regenerate regardless of the underlying medical indication (e.g. aging, cancer, 
trauma), RM is poised to transform the therapeutic landscape in much the same way as 
antibiotics and biotechnology did in previous decades. Antibiotics transformed the treatment of 
bacterial infections in the 1940s, and in the process enabled the emergence of the big pharma 
industry. Recombinant proteins and monoclonal antibodies produced the next industry step 
change, and launched the biotechnology sector. RM technologies, like cell and gene therapies, 
are the most recent major advancement in healthcare, and represent a significant commercial 
opportunity.4  
There are many challenges facing the successful introduction of RM into the clinic, and 
these apply to a greater or lesser extent in all the major regions of the world where medical 
innovation is taking place. These challenges include limited funding due to uncertain commercial 
pathways,5 challenges facing reimbursement and clinical uptake for therapies that are very 
different from conventional drugs,6 and significant manufacturing and scale-up challenges at 
various stages of clinical development.7 All of these challenges are compounded by regulatory 
and policy systems designed for conventional small-molecule drugs, which are struggling to 
adapt to the emergence of radically new therapeutic paradigms.8  
The regulatory agencies of the three major drug-development regions in the world – 
Europe, Japan & the US – are struggling to make appropriate regulatory decisions about 
advanced technologies that are highly promising, but also uncertain and potentially risky – the 
so-called regulatory paradox.9 Is regulatory science (RS), applying science-based approaches and 
standards to support regulatory decision-making, the right set of tools for calibrating a uniform 
set of regulatory mechanisms needed to integrate RM into the mainstream of the development 
continuum for medical products? We will examine the current state-of-the-art for RM and RS in 
the 3 major drug development regions to answer this question. 
     
WHAT IS REGENERATIVE MEDICINE? 
At a conceptual level, RM can be defined by three interrelated approaches: 
 Rejuvenation, which means boosting the body's natural ability to heal itself. Cells in the 
body once thought to be no longer able to divide (terminally differentiated) — including the 
highly specialized cells constituting the heart, lungs and nerves — have been shown to be 
able to remodel and possess some ability to self-heal.  
 Replacement involves using healthy cells, tissues or organs from a living or deceased 
donor to replace damaged ones, and expanding opportunities for organ transplants by finding 
ways to overcome the ongoing donor shortage, the need for immunosuppression and 
challenges with organ rejection. 
 Regeneration involves delivering specific types of cells or cell products to diseased 
tissues or organs, where they will restore tissue and organ function. This can be done through 
cell-based therapy or by using cell products, such as growth factors, or bone marrow 
transplants.10 
 
At a practical level, RM can be defined as products incorporating viable cellular components 
intended to repair, replace or restore diseased, damaged or missing tissues (i.e., ‘healing from 
within’),11 which can be broken down into the following categories (see Table I): 12 
 
Cell Therapy – is the use of living cells as therapies, ranging from established techniques 
such as bone marrow transplantation to more novel approaches using stem cell biology.13 Stem 
cells have the ability to develop — through a process called differentiation — into many 
different types of cells, and offers new clinical applications to treat or manage chronic diseases 
such as diabetes, heart failure, and degenerative nerve, bone and joint conditions. RM 
researchers are investigating both adult and embryonic stem cells, as well as various types of 
progenitor cells, such as those found in umbilical cord blood, and bioengineered cells called 
induced pluripotent stem cells (iPS). The latter are adult cells that have been genetically re-
programmed to an embryonic cell-like state, and are particularly useful for studying 
neurodegenerative diseases like Alzheimer’s, because, among other advantages, they allow 
scientists to study the very early stages of the disorder.14  
 
Gene therapy – is the therapeutic manipulation of individual genes or cell populations for 
the treatment of a disease. For example, several inherited immune deficiencies have been treated 
successfully with gene therapy. In the most common technique, blood stem cells are removed 
from patients, and retroviruses are used to deliver working copies of the defective genes before 
the cells are returned to the patient. Because the cells are treated outside the patient's body, the 
virus will infect and transfer the gene to only the desired target cells. Others are looking to 
expand this approach to mainstream diseases with gene therapy involving the delivery of 
beneficial genes to over-express their products at a site of damage in the body; for example, 
using the common cold virus to deliver the gene that grows new blood vessels (VEGF) to the 
heart in patients with angina.15 
 
Tissue engineering – is using advanced materials and nanomaterials combined with cells 
to produce functional tissues and organs by means of combining cells, biologically active 
molecules, and scaffolds that support the tissue growth until it generates functional tissue (the 
field also includes bio-aesthetic medicines, i.e., medical therapies that generate new and 
aesthetically appealing tissues).  
 
TABLE I 
Therapy Indication Product Manufacturer 
Cell 
Therapy 
Advanced leukemias T cell-based 
immunotherapies for acute 
lymphoblastic and chronic 
lymphocytic leukemias 
UPenn/Novartis; Juno 
Therapeutics 
  Cartilage regeneration in the 
knee 
Carticel, ChondroCelect Aastrom Biopharmaceuticals 
(now Vericel Corp.); TiGenix 
  Cardiac disease - Chronic 
heart failure 
Adult stem cells  Mesoblast/Teva 
Pharmaceuticals 
Gene 
Therapy 
Hemophilia  Factor 9 deficiency St. Jude’s/University College 
London; Spark Therapeutics; 
Baxter International Inc. 
  Inherited metabolic disease - 
familial lipoprotein lipase 
deficiency 
Glybera UniQure 
  Inherited immunology 
disorders  
Severe combined immune-
deficiency (SCID)  
GlaxoSmithKline/Molmed 
Tissue 
Engineering 
Chronic venous leg ulcers– 
Tissue-engineered skin 
replacement 
Apligraf, Dermagraft Organogenesis 
  Diabetic foot ulcers - 
Tissue-engineered skin 
replacement 
Apligraf Organogenesis 
  Corneal blindness – Adult 
stem cell-based therapy  
Holoclar Chiesi 
  Severe burns – Tissue-
engineered skin 
Epicel Aastrom Biopharmaceuticals 
  Gum regeneration – tissue-
engineered soft tissue to 
restore healthy gums 
GINTUIT Organogenesis 
 
 
  
ROLE OF REGULATORY SCIENCE IN REGENERATIVE MEDICINE  
The regulatory agencies of the three major markets all use the term regulatory science, 
but have assigned different priorities for its implementation and employ different methods for 
utilizing it, particularly with regard to RM. In other words, they define it similarly, but apply it 
differentially. 
 
Europe 
Regulatory science is defined by the European Medicines Agency (EMA) as the range of 
scientific disciplines that are applied to the quality, safety and efficacy assessment of medicinal 
products and that inform regulatory decision-making throughout the lifecycle of a medicine 
especially in areas of emerging and innovative sciences. It encompasses basic and applied 
medicinal science and social science, and contributes to the development of regulatory standards 
and tools.16, 17 The primary impetus for its emergence was its applicability to advanced 
technologies in Europe through the adoption in 2007 of Regulation (EC) 1394/2007 on 
Advanced Therapy Medicinal Products (ATMP Regulation), which specifically enumerated 3 
types of ATMPs: gene therapy; somatic cell therapy; and tissue engineered products.18 The 
European ATMP regulation forms part of the centralized procedure for the approval of new, 
advanced medicines to create a viable pathway to market for therapies that could not easily be 
evaluated and given a market authorisation through conventional regulatory processes. It 
includes four key measures. First, the ATMP created a central marketing authorisation procedure 
for all advanced therapies, including both autologous (i.e., patient is the donor) and allogeneic 
(another person is the donor) cell therapies and tissue-engineered products.19  RM based on 
extensively manipulated cells, or those modified on an engineered process, are subject to the 
regulation. Unmodified cells used in transplants do not fall within the regulatory framework, so 
the regulation does not try to capture technologies and techniques that have been used routinely 
for decades. Second, the ATMP included the establishment of a Committee for Advanced 
Therapies (CAT) within the EMA to provide technical advice and establish guidelines for good 
regulatory science. Third, the regulation established special incentives to support innovation in 
small and medium-sized companies, which are driving most of the path breaking science and 
technology underpinning RM. Fourth, the ATMP made a distinction between ‘hospital-based’ 
and ‘commercial research,’ by allowing for what is controversially known as the ‘hospital 
exemption’ (HE) for autologous treatments.20 The HE was to allow experimental treatments to be 
developed and delivered within hospitals for patient benefit, without medical practitioners having 
to apply for a full market authorization and meet strict regulatory requirements. However, these 
products were still expected to meet safety and quality standards set by national regulatory 
bodies.  
 
Japan  
In Japan, regulatory science refers to the science of predicting, evaluating, and 
determining, fairly and promptly, the quality, efficacy, and safety of pharmaceuticals, medical 
devices, and RM products, based on scientific knowledge.21  In April 2009, the Pharmaceuticals 
and Medical Devices Agency (PMDA) established an Office of Regulatory Science (ORS)  and a 
Regulatory Science Research Division in ORS. In 2011, they established the Office of Standards 
and Guidelines Development, a dual structure office with the Division of Standards for Drugs 
and the Division of Standards for Medical Devices, through which they are developing standards 
and guidelines by systematizing the review information as well as the outcomes of research on 
regulatory science. In 2012, PMDA established a Science Board of external experts to pursue 
regulatory science, enhance cooperation and communication with academia and medical 
institutions, and keep pace with the advancing science and technology utilized in the products.22 
At a practical level, the primary application of regulatory science in Japan has been to 
facilitate development and review of RM. Japan has one of the highest proportions of aged 
individuals globally, and cell and tissue based products were beginning to show promise for 
addressing the consequent health problems, however, regulatory oversight in the new field of 
RM was outdated and inadequate. For these reasons, in April of 2013, Japan passed the 
Regenerative Medicine Promotion Act to establish the government’s responsibility to regulate 
RM.23 This stage-setting legislation was soon followed by the “The Act on the Safety of RM” 
and the “Pharmaceuticals, Medical Devices and Other Therapeutic Products Act” (PMD Act), 
which created the current regulatory framework. The former law promotes RM by facilitating 
clinical studies, while ensuring safety with oversight of in-house clinical research and medical 
practice, as well as assuring quality with standards in good tissue practice (GTP), while allowing 
outsourcing of cell culturing and processing.24 The latter permits a product sponsor to get 
conditional marketing approval based on results from mid-stage, or Phase II, human trials that 
demonstrate safety and probable efficacy. Conditional approval means that the firm will be able 
to sell its treatment while continuing to gather data on efficacy for a period of up to seven years. 
At the end of the seven year period, the firm must either apply for final marketing approval or 
withdraw the product.25 Proponents of the regulatory upgrade believe that now there is an 
approximately three-year trajectory for approvals compared with seven to 10 years before the 
laws’ implementation.26 
 
United States 
Regulatory Science, as defined by FDA, is the science of developing new tools, 
standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA-
regulated products. On February 24, 2010, FDA launched its Advancing Regulatory Science 
Initiative, building on the achievements of existing programs, like Critical Path. Its 
implementation is overseen by the Office of Regulatory Science and Innovation. According to 
FDA, stem cells, engineered tissues, and combination products are areas of rapidly emerging 
technology for which intervention will be necessary to bridge the gap between innovation and 
the market. FDA recognizes the importance of RM and has made an effort to interact with the 
development community and NIH to consider standards and models in this area.27 Indeed, FDA’s 
global engagement strategy proposes a strong reliance on regulatory science to ensure that FDA 
is engaging with global partners to harness scientific developments and pool products, resources, 
and expertise to support science-based regulatory decision-making and pursue the best public 
health solutions.28 
On the one hand, FDA scientists appear to use most of the FDA’s allotted RM funds 
(about $8.63 million) to advance regulatory science, such as improving methods for evaluating 
experimental cell-based products to reliably predict product performance. On the other hand, 
Table II 29 illustrates how FDA’s Regulatory Science strategy is viewed by some observers as 
applying to RM/Stem Cell Science only in broad strokes.   
 
 
  
TABLE II  
Regulatory science strategic area Examples of relevance for stem cell–based 
regenerative medicine 
1. Modernize Toxicology to Enhance 
Product Safety 
 
NIH NCATS grant: Human induced pluripotent stem 
cell and embryonic stem cell-based models for 
predictive neural toxicity and teratogenicity 
2. Stimulate Innovation in Clinical 
Evaluations and Personalized 
Medicine to Improve Product 
Development and Patient Outcomes 
NIH NCATS grant: Modeling complex disease using 
induced pluripotent stem cell-derived skin constructs 
3. Support New Approaches to 
Improve Product Manufacturing and 
Quality 
Quality by Design in Stem Cell Transplantation 
4. Ensure FDA Readiness to 
Evaluate Innovative Emerging 
Technologies 
Participation in public hearings of the FDA advisory 
committees on market authorization applications in 
respect of stem cell–based regenerative medicines 
5. Harness Diverse Data through 
Information Sciences to Improve 
Health Outcomes 
Application of the technology embodied in the Stem 
Cell Matrix, an innovative information system  
6. Implement a New Prevention-
Focused Food Safety System to 
Protect Public Health 
The use of stem cell lines for food safety tests 
 
7. Facilitate Development of Medical 
Countermeasures to Protect Against 
Threats to U.S. and Global Health 
and Security 
U.S. Biomedical Advanced Research & Development 
Authority (BARDA): Mesenchymal Stem Cells to 
Mitigate and Treat Cutaneous Injury Following 
Radiation; Irradiated Hosts on Transplanted 
Hematopoietic Stem Cells 
8. Strengthen Social and Behavioral 
Science to Help Consumers and 
Professionals Make Informed 
Decisions about Regulated Product 
References to FDA's efforts at community outreach in 
November 2012 report on the elements of regulatory 
science applicable to RM&SC by the Office of Cellular, 
Tissue and Gene Therapies in FDA's Center for 
Biologics Evaluation and Research. 
 
 
CURRENT STATE-OF –THE –INDUSTRY FOR REGENERATIVE MEDICINE 
 
 
Market Value Estimates 
Predictions for global market for RM products in 2020 range from as low as $11 billion,30 
to as high as $ 67.6 billion, at a cumulative annual growth rate (CAGR) of 23.2% during the 
years 2014 and 2020.31 According to a recent market research report, North America and Europe 
accounted for over 75% of the market revenue in 2013 and is projected to be the most lucrative 
regional market. However, there is believed to be an increase in technological adoption and 
emphasis on RM research in Japan and South Korea, with the Asia-Pacific region as a whole 
considered to be the fastest growing region for the RM market.32 Japan’s market alone is poised 
to grow from 9 billion yen in 2012 to 1 trillion yen in 2030.33 It is no surprise that many analysts 
feel the sector is entering a significant inflection phase,34 because of a convergence of key 
market factors including: an ever-aging population, increasing patient expectations, diminishing 
Big Pharma pipelines, and significant corporate investment by the majority of the Big Pharma 
companies.35  
Unmet medical needs that could be addressed by RM therapies provide additional support 
for this assessment. In Europe, for example, primary immune deficiencies (PIDs) are a growing 
group of over 230 different disorders exemplified by the condition, ADA-SCID, also known by 
its media moniker as the "bubble boy disease." By itself ADA-SCID is commercially a very 
small market, however, the field has potential to widen into the mass-market condition of heart 
failure.36 In Japan, there are over 4.6 million people living with Alzheimer’s Disease, and by 
2050, the socio-economic cost will be greater than the Japanese government’s annual income 
unless effective treatment becomes available.37 In the US, there are 132 million MD office visits, 
29 million ER visits, and 15 million out-patient visits for musculoskeletal-related conditions per 
year with estimated annual direct and indirect healthcare costs of $850 billion.38  
 
 
R&D Funding  
Overall, the RM investment horizon has brightened considerably according to highlights 
from the Investors Day meeting held by the Alliance for Regenerative Medicine (ARM) in late 
March of 2015: venture capital investments nearly doubled; funding from initial public offerings 
(IPOs) were close to tripling; and, up-front partnership payments rose almost 8-fold.39  
In Europe, a recent spate of deals has ignited investor interest in gene therapy and several 
large drug-makers are now buying into a high-risk field that is recovering from some disastrous 
clinical trial results in the late 1990s and early 2000s. In 2014, gene therapy attracted $3.0 billion 
in financing, up 510% on 2013, and the pace has continued in 2015.40 The European 
Commission’s Horizon 2020 funding call, together with the Innovative Medicines Initiative, will 
provide over 10 billion euros in research funding opportunities over the next 5 years, making the 
EU more attractive than ever for gene and cell therapy sector possibilities to create innovative 
consortia in collaboration with industry, bring novel products to market, and build sustainable 
networks of expertise in the field.41  
In Japan, the Forum for Innovative Regenerative Medicine (FIRM) was incorporated in 
2011 to pursue broad, industry-led partnerships with governments, universities, and the private 
sector for the purpose of building a great consensus on the commercialization process. It 
currently consists of 185 member companies from a half dozen industrial sectors involved in 
RM, including 43 biotechnology and pharma companies.42 In April 2015, establishment of the 
Japan Agency for Medical Research and Development (AMED), including a Division of 
Regenerative Medicine Research, enabled Japan to build a centralized public research funding 
system for research and development, including RM. 43  
In the US, a major source of basic research funding for RM comes from the National 
Institutes of Health (NIH). It is divided among the following categories: translational research; 
clinical research; specific population research (wounded soldiers); and research to advance 
regulatory science. Over the period 2012-2014, funding from the NIH   was $2.54 billion, with 
an additional $359 million for RM being invested by six other government agencies, mostly by 
the Department of Defense.44 
 
 
 
R&D Pipeline and Products 
According to the Alliance for Regenerative Medicine (ARM), an advocacy organization 
for RM, approved RM products have been used to treat in excess of one million patients. In 
addition, there are several hundred thousand peer-reviewed publications, 10,000+ issued/pending 
patents, and well over a 100 programs in leading academic centers as well as several billion 
dollars in funding for research and translation spread across North America, Europe and Asia. 
Products in development include several hundred cell-based therapies, small molecules, 
biologics, tissue-engineered cells and materials and implantable devices. Additional products use 
cells as drug discovery or toxicity testing tools as well as clinical tools, bio-processing tools and 
platforms that include equipment, consumables, reagents and storage systems, according to the 
ARM website. Globally, there are over 700 private and 60 public companies in the RM sector 
(combined market capitalization of over $10 billion). As of the 2nd quarter of 2015, there were 
528 clinical trials that included RM products: 169 in phase I; 304 in phase II; and 55, in phase 
III. Nearly 40% of current clinical trials are in oncology while more than 10% are in 
cardiovascular.45 To date only 30 cell and gene-based therapies have received regulatory 
approval in the U.S., Europe, and/or Japan (see Table III).46 Around the world, companies have 
faced challenges in bringing treatments to clinic. Even in the U.S., where the overall innovation 
environment has usually been the most favorable, Geron Corp., which started the first nation-
approved trial of human embryonic stem cells, ended the program in 2011, citing research costs 
and regulatory complexities.47  
 
Regulatory Environment Complexity  
In Europe, one of the challenges with regulation of advanced technologies is that they are 
typically developed on a small scale, in academic settings or small enterprises where regulatory 
compliance may be disproportionately burdensome, and EMA recognized that this was making it 
difficult for small and medium-sized entities (SMEs) to bring advanced therapies to market. In 
fact, a recent report on the ATMP regulation noted that 70% of the clinical trials being conducted 
in this field are by non-profits and SMEs.48 In response, Europe has become the leader in 
developing specialized regulations in the area of cell and tissue-based therapies with its adoption 
of the ATMP Regulation. Other incentives included mechanisms such as fast-track assessment, 
fee reductions, and use of orphan drug legislation, where appropriate.49   
In fact, such fast-tracking measure is the route that Japan took with its special legislation 
for RM (discussed earlier). In the US, FDA went in a different direction, organizing workshops 
on specific scientific questions, as well as using its existing authority to issue industry guidance 
and to designate eligible programs for expedited development and approval programs. It also 
provided an additional avenue for regulatory relief depending on whether product 
characterization met one set of criteria versus another. Under U.S. law, stem cell-based therapies, 
for example, would be considered “human cells, tissues, or cellular or tissue-based products” 
(HCT/Ps), which are defined as “articles containing or consisting of human cells or tissues that 
are intended for implantation, transplantation, infusion, or transfer into a human recipient.” 
Category Section 361 are subject only to requirements for HCT/Ps which include establishment 
registration and product listing, donor eligibility, and current Good Tissue Practice (cGTP), 
while category Section 351 are subject to additional regulation as drugs or biological products. 
Cell therapy, for example, would meet the definition of a drug as well as a biological product and 
would have to comply with cGMP standards.50  
 
TABLE III 
Country  Approved Product and Related Devices  Manufacturer 
United States  ALLOCORD, HPC Cord Blood SSM Cardinal Glennon Children's Medical 
Center 
  Autologous Cultured Fibroblasts Laviv (Azficel-T), Fibrocell Technologies 
  Autologous Cultured Chondrocytes Carticel, Genzyme BioSurgery 
  BCG Live (Intravesical) TheraCys, Sanofi Pasteur Limited Lic#1726 
  GINTUIT (Allogeneic Cultured 
Keratinocytes and Fibroblasts in Bovine 
Collagen) 
Organogenesis Incorporated 
  Hematopoietic Progenitor Cells, Cord Blood Hemacord, New York Blood Center 
  Hematopoietic Progenitor Cell Ducord, HPC Cord Blood, Duke University 
School of Medicine 
  HPC, Cord Blood Clinimmune Labs, University of Colorado 
Cord Blood Bank 
  HPC, Cord Blood BLA 125432 LifeSouth Community Blood Centers, Inc. 
  PROVENGE (sipuleucel-T) Dendreon Corp. 
 Apligraf (Graftskin) Organogenesis 
 OrCel Ortec 
 Dermagraft Advanced BioHealing 
 Dermagraft-TC Advanced Tissue Science 
 Epicel Genzyme 
 Integra Artificial Skin Integra LifeSciences Corp.  
 Celution Cytori Therapeutics 
 GEM 125 BioMimetic Therapeutics, Inc 
 Regranex Smith and Nephew Inc 
 Infuse, Infuse bone graft Medtronic Sofamor Danek 
 Osteogenic protein-1 Stryker 
Europe Glybera  UniQure 
  Chondrocelect Tigenix  
  Holoclar  Chiesi Farmaceutici 
Japan  Temcell HS Inj.  Mesoblast;JCR Pharmaceuticals Co Ltd 
 Heart Sheet Terumo Corp. 
 JACE® (Autologous cultured epidermis) Fujifilm Group company Japan Tissue 
Engineering Co., Ltd. 
 JACC® (Autologous cultured cartilage)  Fujifilm Group company Japan Tissue 
Engineering Co., Ltd. 
 
Despite these efforts, RM stakeholders such as ARM, the California Institute for 
Regenerative Medicine (CIRM), and even the US congressional watchdog agency (GAO) have 
emphasized that more radical changes to the regulatory environment in Europe and the US are 
needed.51,52,53 Among the factors contributing to the need for enhancements of  current regulatory 
regimes are the small numbers of patients available for clinical testing of breakthrough 
technologies, which often involve treatments highly specific to small sub-populations of patients, 
or even single patients.  Safety and efficacy testing of such treatments require more flexible 
regulatory approaches that can handle large amounts of complex data and explore multiple 
causal factors simultaneously, including individual patient responses, in order to ascertain 
outcomes data for combinations of biochemical and molecular factors that recur in groups of 
patients.54 The FDA Science Board summarized similar  concerns in its recent report, and 
concluded that among the most important remedial measures needed were: new authority and 
increased funding to improve FDA’s ability to manage new and emerging technologies, 
including stem cells, and advances in regulatory science that promote the lifecycle approach to 
regulation for drugs, devices and biologics.55Lastly, for reasons not dissimilar to the ones voiced 
regarding the need for adopting changes to current  regulatory regimes to accommodate RM – 
emerging product classes posing unique regulatory challenges, regulatory frameworks in 
different states of maturity from region-to-region without applicable international conventions 
such as ICH, concerns about medical tourism based on the lack of regulatory controls – a clarion 
call for harmonization, or at least a so-called “regulatory convergence” of shared perspectives on 
standards, is being heard from many quarters.56,57,58,59  
 
PROSPECTS FOR HARMONIZATION: ARE THE OBSTACLES PRACTICIAL OR 
POLITICAL?  
Among the practical obstacles to harmonization is the fact that unmet medical needs and 
medical practices vary in the three major markets under discussion. Furthermore, they represent 
different legal jurisdictions and health care systems, with disparate regulatory and reimbursement 
requirements for both conventional and advanced therapies. Nevertheless, RM has broad 
potential to address multiple disease conditions with a variety of therapeutic modalities. The 
FDA has said it does not want to establish a separate pathway for RM, while the EMA and 
MHLW have done that albeit in ways that are similar to expediting mechanisms that FDA 
already has at its disposal. While the FDA can use ‘enforcement discretion’ to enforce existing 
regulations with more flexibility, the EU hospital exemption would probably not work because 
there is no state or provincial authority equivalent to Member State sovereignty. While US states 
have authority to regulate medical practice and facilities, they cannot regulate products that will 
cross state lines in commerce. Nevertheless, another regulatory innovation is progressive or 
adaptive licensing regimes, which allow initial market access based on preliminary data. This is 
essentially what Japan uses, and the FDA and EMA could modify their own versions – 
accelerated approval and conditional approval, respectively – to make them fit-for-purpose for 
RM. Even in the Ebola crisis, some urgent level of response under difficult conditions was 
achieved using a variety of such special programs. Perhaps it is not the practicality of 
legitimizing new authority that should be the focus of the debate, but rather, as both patient 
advocates and regulatory affairs experts have stressed, the importance of enhanced collaboration 
among regulatory authorities.60  
There is, however, a political ambit within which regulatory agencies must operate, and 
often the operative factor is maintaining global competitiveness for its commercial stakeholders. 
Due to its size and lack of price controls, the US pharmaceutical market is the most lucrative in 
the world. This means that the US has an outsize influence on total world investment.61  The 
Europeans and Japanese view their Regulatory Science initiatives as means to increase their 
global competitiveness. However, so far historical events have contributed to a de facto state of 
commercial détente. When the US Congress banned federal funding in 1995 for research on 
embryos—and thus the development of new stem cell lines—scientists found their work had 
ground to a halt. Yet scientists in Japan developed iPS cells that would eliminate the need for 
embryonic stem cells and allow researchers to create stem cells from the individuals who were 
suffering from the diseases they were studying.62 At about the same time, the promising new 
field of gene therapy experienced a blow from the high-profile death of an American patient in 
1999 and cases of leukemia in French children a few years later. However, Europe did not 
abandon gene therapy and went on to further advance the field, while the U.S. retreated after the 
earlier setbacks.63 This led to different trajectories for the primary RM therapeutic modalities in 
the three regions. But as big pharma increases its appetite for small-volume, high-dollar 
products, it remains to be seen if incipient markets for novel products like gene therapy quickly 
become crowded as is happening with personalized medicines for certain cancer indications. In 
that case, we may see a waning of the current atmosphere of biomedical business bonhomie. 
Nonetheless, even in the face of increasing political pressure promoting global competition, there 
is countervailing rationale for adopting a harmonized framework based on similar RS-driven 
processes for regulatory development and approval programs in order to lower R&D costs by 
increasing the opportunity for risk-sharing and resource-sparing collaborations across country 
and sector lines, and to increase market access without resort to medical tourism.  
In response to RM advocacy groups and other stakeholders in Europe and the US calling 
for discussions on international regulatory harmonization to foster global consistency of 
regulatory policy, and where possible, to facilitate more rapid and efficient introduction of RM 
products,64,65 the EMA and FDA are continuing to have that dialogue in cell and gene therapy 
regulators forums. Japan, for its part, is advancing a global-level regulatory science program to 
improve the predictability and transparency of regulatory approvals and enhancement of safety 
measures, and in response to calls for harmonization, will incorporate release of more 
information in English by PMDA, in particular through an English version of its website.66 
Lastly, Japan intends to build a framework for international dialogue, including with Europe and 
the US, to establish agreed minimum study data requirements for pre-market reviews of RM 
products and product quality assurance, through the efforts of its global unit within MHLW to 
implement Japan’s International Pharmaceutical Regulatory Harmonization Strategy.  Despite  
considerable cooperation and collaboration in holding joint meetings and ongoing discussion of 
technical approaches to advanced therapy evaluation among the regions through Regulators 
Forums,67,68,69 real progress toward full regulatory harmonization, or even ‘convergence’ on a 
regulatory science approach to RM, has been slow. 
Europe has been active in the area of regulatory science but is understandably focused on 
ironing out discrepancies among EU’s member states, while Japan now turns its attention to 
influencing its ASEAN and other neighbors. In the US, FDA has expressed ambivalence calling 
regulatory science “unique but neglected,”70 and lamented that while FDA recognizes the 
importance of RM, its funding was limited.71  While Europe and Japan are making inroads in 
advancing RM technology, particularly in gene therapy and stem cell science, respectively, 
commercial viability of the sector will stay tentative without the US market, and the overall 
investment climate will vacillate precariously. In the US, attention is being paid to addressing 
new technologies, but RM is one among many – nanotechnology, bioinformatics, and precision 
medicine – that seem to have broader and less controversial appeal politically-speaking. 
Development of regenerative medicine will not advance at a pace consonant with its promise 
without a concurrent advance in the development of a flexible regulatory framework that 
facilitates innovation while integrating approaches to manage scientific uncertainty – the tools 
and trademark of regulatory science.      
 
 
CONCLUSION 
RM is a sector with major commercial and investment opportunities as well as the 
potential to change the focus of medical practice from managing chronicity with “band-aid 
therapies” to meting out cures, with additional positive implications for achieving cost-effective 
and affordable health care solutions by “healing the body from within.” The field has reached an 
especially critical juncture in 2016 as positive findings addressing the question of whether stem 
cells will develop normally once transplanted into an embryo have recently been published.72, 73 
If replicated, these findings could have significant implications for allaying some of the safety 
concerns that surround stem cell research, and the clarion call by patients, practitioners, and 
providers for a shift from traditional to transformative medical treatment paradigms will grow 
more emphatic.  Just as consistent and predictable regulatory frameworks founded on common 
principles in regulatory science provide the confidence and certainty required to bolster 
investment to advance the field of regenerative medicine, harmonization is essential to building 
that framework on a global scale. Without some determined intervention in the next few years by 
the public health agencies of Europe, Japan and the United States to harmonize approval 
pathways and risk assessment parameters, the scientific, regulatory, and funding uncertainties 
will continue to loom large while prospects for meaningful change will remain small on a distant 
horizon. 
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